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Abstract
Background: Gut-derived bacterial endotoxin is an important cofactor in the pathogenesis of IBD. Regulatory T
cells (Tregs) are essential for maintenance of peripheral tolerance and can prevent and alleviate IBD. To determine
the immune modulatory effect of anti-LPS enriched hyperimmune colostrum, its ability to induce Tregs and
alleviate immune mediated colitis.
Methods: Immune-mediated colitis was induced in mice by intra-colonic instillation of Trinitrobenzene Sulfonate
(TNBS). Four groups of mice were orally administered with two dosages of IgG-enriched colostrum fractions. The
fractions were harvested from cows immunized against LPS derived from intestinal Escherichia coli bacteria
(Imm124E). Control mice received non-immunized colostrum or vehicle (PBS). Treatment was administered one day
following sensitization and four additional days following the administration of TNBS. The following parameters in
the mice were tracked: body weight, bowel histology, serum cytokine levels and regulatory T cells.
Results: Oral administration of Imm124E hyperimmune colostrum ameliorated immune-mediated colitis. Significant
amelioration of weight reduction was noted in treated mice. Oral administration of Imm124E improved bowel
histology. Both the extent of the disease, inflammation score, and colitis damage and regeneration scores
decreased in Imm-124E treated animals. These effects were associated with an increase in serum IL10 anti
inflammatory cytokine levels, and an increase in CD4 + CD25+ and CD4 + Foxp3+ Tregs.
Conclusions: Oral administration of Imm124E promoted Tregs and alleviated bowel inflammation in immune
mediated colitis. The present data suggests that the microbiome may serve as a target for Tregs-based
immunotherapy.
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Background
The human gut is a natural environment for a dynamic
microbial ecosystem associated with immune mediated
disorders [1]. Several disease states have been associated
with changes in the composition of fecal and intestinal mu-
cosal communities, including inflammatory bowel diseases
(IBD), obesity and metabolic syndrome [1]. Chronic inflam-
mation involves endotoxins derived from the gut flora.
Endogenous gut-derived bacterial endotoxin has been
considered an important cofactor that mediates the
pathogenesis of IBD [2]. Aberrant immune responses to-
ward commensal gut bacteria result in the onset and
perpetuation of IBD [3]. Reduced microbiotic diversity
in conjunction with a lower proportion of Gram positive
and higher proportion of Gram negative bacteria com-
pared with that of healthy subjects is reported in IBD
patients [3]. In a subset of IBD patients, E. coli strains
with specific features trigger activation of the disease.
Antibiotics can decrease tissue invasion and eliminate
aggressive bacterial species [2]. They are used in IBD to
treat infective complications and also for altering bacter-
ial flora, which may result in specific anti-inflammatory
effects. Therapeutic manipulation of the intestinal flora
offers considerable promise for treating IBD [2].
Regulatory T cells (Tregs) have been demonstrated to
be essential for maintaining peripheral tolerance, pre-
venting autoimmune diseases and limiting chronic in-
flammatory diseases [4]. Induction of mucosal tolerance
is effective in the treatment of autoimmune and inflam-
matory diseases due to the lack of toxicity, ease of ad-
ministration and antigen-specific mechanism of action
[5]. Oral administration of anti-CD3 antibodies induces
Tregs through a TGF-β-dependent mechanism, alleviat-
ing immune mediated disorders including colitis.[6–9].
Bovine colostrum (BC) contains abundant bioactive
components including growth factors, immunoglobulin
(Igs), lactoperoxidase, lysozyme, lactoferrin, nucleosides,
vitamins, peptides and oligosaccharides [10, 11]. Colos-
trum is also rich in cytokines and other immune agents
that provide bacteriostatic, bactericidal, antiviral, anti-in-
flammatory and immunomodulatory protection against
infection [12, 13]. Hyperimmune colostrum raised against
a bacterial LPS extract (Imm124-E, Immuron Ltd,
Melbourne, Australia) was shown beneficial in animal
models of immune-associated insulin resistance and non-
alcoholic steatohepatitis [14]. These beneficial effects
were associated with an increase in the number of
splenic CD4 + CD25+, CD4 + CD25 + Foxp3+ and CD3
+ NK1.1+ regulatory lymphocytes. In humans with
metabolic syndrome, oral administration of Imm124-E
was safe and alleviated insulin resistance, liver damage,
and hyperlipidemia [15]. These effects were accompan-
ied by increased serum levels of glucagon-like peptide 1
(GLP-1), adiponectin and Tregs.
The aim of the current study was to determine in
experimental TNBS-induced colitis the effects of hyper-
immune colostrum preparations enriched with IgG-
enhanced colostrum fractions. These colostrum prepara-
tions were harvested from cows immunized against LPS
from intestinal bacteria (Escherichia coli, Imm124E). Our
results indicate that oral administration of Imm124E
promoted Tregs and alleviated the inflammatory state in
this model.
Methods
Colostrum collection and processing
Colostrum preparations were prepared and provided by
Immuron Ltd. (Melbourne, Australia). Colostrum was
collected from immunized or non-immunized cows
(colostrum control) and was frozen in individual bags.
Each batch was subsequently pasteurized and concen-
trated by ultra-filtration before freeze-drying. Colostrum
preparations were manufactured and tested by an accre-
dited testing lab (Dairy Technical Services, Melbourne,
Australia) with regard to specifications for the levels of
IgG protein, moisture, lactose, fat, antibiotics and micro-
biology parameters. All first-milking colostrum powder
preparations contained approximately 40 % IgG (w/w).
All freeze-dried bovine colostrum powders were emulsi-
fied in water and stored at 4 °C prior to administration
to mice.
E. coli antigens
Killed bacterial antigens from the single ETEC strain
(O78) vaccine or from the multiple ETEC strain vaccine
(O6, O8, O15, O25, O27, O63, O114, O115, O128, O148,
O153 and O159 serotypes) were used as a source of
antigen for coating ELISA plates. Stock antigens were pre-
pared according to the manufacturer’s instructions (Allied
Biotechnology, Australia). LPS from Enterotoxigenic E.
coli (ETEC) colostrum was designated as Imm124-E. IgG
purified from Imm124-E was prepared using a Prosep G
column to purify colostrum powder [14]. An in house
ELISA test was used to assess the levels of immunoglobu-
lin in the powder as described [14].
Animals and experimental design
Male, Balb/c, 7–8 week old mice were purchased from
Harlan (Jerusalem, Israel). Mice were maintained in the
Animal Core of the Hadassah-Hebrew University Medical
School. All mice were administered standard laboratory
chow and water ad libitum and maintained under a 12 h
light/dark cycle.
Induction of colitis
To induce TNBS- colitis, mice were exposed by skin
painting with 160 μL of the haptenizing agent TNBS
(Sigma-Aldrich, Rehovot, Israel) at a concentration of
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2.5 % in 50 % ethanol on day −7. On day 0, 120 μL of
2.5 % TNBS in 50 % ethanol was administered intrarec-
tally via a 3.5-French catheter which was carefully
inserted into the colon ensuring that the tip was 4 cm
proximal to the anus. Four groups of mice (4 mice per
group) were orally administered either vehicle (PBS);
100 μg of colostrum control; 50 μg of Imm124-E, or
500 μg of Imm124-E daily, starting one day following
intrarectal administration of TNBS and for four
additional days following administration of TNBS, and
then sacrificed.
Follow up of the effects of Imm124E on immune
mediated colitis
a. Effect on body weight:. Mice were weighed on
day −7 (beginning of experiment), on day 0
(intrarectal TNBS) and on the sacrifice day.
b. Grading of colon histology: For histological
evaluation of the inflammation, distal colonic tissue
(last 10 cm) was removed after the mice were
sacrificed, and then fixed in 10 % formaldehyde.
Paraffin sections from each animal were then stained
with hematoxylin- eosin according to standard
techniques. The degree of inflammation, its extent,
damage and regeneration seen on microscopic cross
sections of the colon was graded from 0 to 3 with
grade 0 being considered normal, as described [16].
c. Effect of cytokine serum levels: Serum levels of IL-10
and IFNγ were determined by “sandwich” ELISA using
a commercial kit according to the manufacturer’s
recommended instructions (Quantikine, R&D Systems,
Minneapolis, MN, USA).
d. Effect on Regulatory T cells: Flow cytometry was
performed following splenocyte and intrahepatic
lymphocyte isolation using 1x106 lymphocytes in
100 ml PBS with 0.1 % BSA. For surface staining,
cells were incubated with fluorochrome-
conjugated antibodies to the indicated cell-surface
markers (eBioscience, San Diego, CA, USA) at the
recommended dilution or with isotype control
antibodies for 30 min at 4 °C. The following cell
surface anti-mouse antibodies were used: CD4-
eFluoro 450, CD8- FITC and CD25-PE. Cells were
then washed in PBS containing 1 % BSA and
fixed with fixation buffer (eBioscience) for another
50 min. For intracellular staining of Foxp3, cells
after fixation were permeabilized with Foxp3
staining buffer (eBioscience). The resulting cells
were stained with PE-Cy7-conjugated antibodies to
Foxp3 (eBiosciences). Cells were then washed twice
and re-suspended in 250 μl of PBS containing 1 %
BSA and kept at 4oC. 1x106 stained cells in 250 μl of
PBS containing 1 % BSA were subsequently analyzed
using a FACS LSR II instrument (Becton Dickinson,
San Jose, CA) with FCS express V.3 software (DeNovo
software, CA, USA). Only live cells were counted, and
background fluorescence from non-antibody-treated
lymphocytes was subtracted.
Statistical analyses
Comparison of the two independent groups was performed
using Student’s t-test. All tests that we applied were two-
tailed, and a p value of 0.05 or less was considered statisti-
cally significant.
Results
Oral administration of Imm-124E ameliorated the weight
loss in immune mediated colitis
Figure 1 shows that oral administration of Imm-124E
was associated with significant weight loss amelioration.
Mice in control groups that received PBS or colostrum
control lost weight (17 % and 16.8 % decrease from
baseline, respectively). In contrast, in the mice treated
with the low and high doses of immunized colostrum,
Imm-124E, we noted a milder decrease in weight (7.5 %
and 7.1 %, decrease, respectively, P = 0.001 and P =
0.002, respectively).
Oral administration of Imm-124E ameliorated the colonic
damage in immune mediated colitis
Figure 2a shows that oral Imm-124E improved colon
histology. The extent of disease decreased from 2.5 and
2.75 in PBS and colostrum control treated mice, com-
pared with 1.75 and 1.75 in the low dose and high dose
of Imm-124E -treated animals, respectively. Similarly,
the inflammation score decreased from 2.75 and 2.5 in
PBS and non-immune colostrum treated mice to 2.25
and 2.0 in the low dose and high dose Imm-124E treated
























Fig. 1 Following the induction of TNBS colitis, mice were monitored
for body weight. Oral administration of Imm-124E ameliorated
weight reduction compared with the control group that received
PBS or non-immune colostrum
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2.25 and 2.65 in PBS and non-immune colostrum
treated mice, to 2.0 and 1.5 in the low dose and high
dose Imm-124E treated animals, respectively; The regen-
eration score decreased from 2.25 and 2.75 in PBS and
non-immune colostrum treated mice, to 1.25 and 1.5 in
the low dose and high dose Imm-124E treated animals,
respectively (P =NS).
Figure 2b shows representative colon sections from
each of the groups. While animals in the control groups
showed signs of inflammation affecting all layers of the
colon mucosa, almost normal mucosal sections were
noted in both the low and high dosage Imm-124E
treated mice.
Oral administration of Imm-124E increased IL10 serum
levels in immune mediated colitis
Figure 3 shows that oral administration of high dose
Imm-124E was associated with an increase in serum levels
of IL10 (p < 0.005 for mice treated with 500 microgram vs.
controls). No effect was noted on IFNγ serum levels.
Oral administration of Imm-124E promoted regulatory T
cells
Figure 4a shows that the high dosage of Imm-124E pro-
moted both CD4 + CD25+ and CD4 + Foxp3+ intrasple-
nic lymphocyte subsets. An increase in CD4 + CD25+
subset was noted in Imm-124E treated mice and in mice
Group A, PBS Group B, Colostrum Control 
























Fig. 2 The effect of oral administration of Imm-124E on colonic damage in immune mediated colitis. a. Histologic scores were performed on bowel
biopsies taken from all mice in all treated and control groups. Sections were scored for extent of disease, degree of inflammation, damage and
regeneration. b. Representative sections from each of the groups are shown (X10). Animals in the control groups showed significant inflammation

























Fig. 3 The effect of oral administration of high dose Imm-124E on IL10 serum levels as measured by ELISA
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treated with colostrums, compared with controls (P =NS).
An increase was noted for CD4 + Foxp3+ in mice treated
with the high dose Imm-124E (P =NS). No effect was
noted on the intrahepatic lymphocyte subsets (Fig. 4b).
Discussion
The results of the present study show that oral adminis-
tration of hyperimmune colostrum preparations enriched
with anti-LPS antibodies that are harvested from cows im-
munized against LPS from intestinal bacteria (Escherichia
coli), ameliorated TNBS-induced colitis. Oral administra-
tion of Imm-124E ameliorated weight loss that was
associated with improved disease clinical course and
colon histology. The extent of disease, inflammation
score, and colitis damage and regeneration scores
decreased in Imm-124E- treated animals. These effects
were associated with increased serum IL10 levels and a
trend towards increased levels of Tregs (CD4 + CD25+
and CD4 + Foxp3+ subsets).
The gastrointestinal tract contains a large and diverse
population of commensal bacteria and is also one of the
primary sites of exposure to pathogens. Intestinal mi-
crobes play a role in both the immune system and in
maintaining metabolic homeostasis [17]. In a healthy
host the immune system is tolerant to gut bacteria and
does not mount an effector response to bacteria-derived
antigens [18]. Thus, the intestinal immune system is
instructed by the microbes to limit responses to luminal
antigens [17]. Gut microbes can inhibit the transport of
both commensal and pathogenic bacteria from the
lumen to the mesenteric lymph nodes (MLNs) [17].
Breakdown of tolerance at the gut level may contribute
to the development of IBD [19]. This breakdown may be
associated with bowel infection. The compartmentalization
of systemic and gut mucosal immunity apparatuses focuses
adaptive immunity on gut microbes specifically at the level
of the bowel. In circumstances of increased gut microbial
exposure due to elevated gut epithelial permeability result-
ing from genetic deficiencies in local defense mechanisms
or during gastrointestinal pathogenic infections, this para-
digm is broken and a systemic immune response towards
gut microbes is induced [20]. The loss of tolerance to com-
mensals during bowel infections leads to activation of
microbiome-specific T cells which differentiate into inflam-
matory effector cells [19]. These T cells may go on to form
memory cells that are pathogen-specific. The response to
commensals during infection in the bowel parallels the
immune response to pathogenic microbes, suggesting that
the adaptive responses against commensals are an integral
component of mucosal immunity [19]. In the absence of
Myd88 or with antibiotic-induced dysbiosis, non-invasive
bacteria were trafficked to MLNs in a CCR7-dependent
manner, inducing an inflammatory response [17].
The data of the present study supports a possible
correlation between specific E. Coli strains and IBD. Fol-
lowing enterocyte stress, translocation of E. coli strains
C25 and HBTEC-1 across Caco-2 monolayers was mark-
edly stimulated and accompanied by an increase in in-
ternalization into the enterocytes. The data suggested
that E. coli strains capable of translocation may comprise
a separate group of E. coli strains [21]. Enteropathogenic
(EPEC) and enterohaemorrhagic (EHEC) strains of E.
coli use a type III secretion system (T3SS) to deliver
virulence effector proteins into host cells during infec-
tion. This system enables bacterial colonization while
interfering with the antimicrobial host response [22]. In
a recent study it was shown that a T3SS effector NleB1
from EPEC binds to host cell death-domain-containing
proteins and thereby inhibits death receptor signaling
[22]. NleB1 prevented Fas ligand or TNF-induced forma-
tion of the canonical death-inducing signaling complex












































Fig. 4 FACS analysis was performed on lymphocytes harvested from spleens (4a) and livers (4b) of animals in all groups. A high dosage of
Imm-124E led to an increase in both CD4+CD25+ and CD4+Foxp3+ intrasplenic lymphocyte subsets. No effect was noted on intrahepatic
lymphocyte subsets
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essential step in death-receptor-induced apoptosis. NleB
activity suggests that EPEC antagonize death-receptor-
induced apoptosis of infected cells, thereby blocking a
major antimicrobial host response [22]. These findings
may be of importance for a possible association between
specific strains of E. Coli and IBD. Increased gut perme-
ability caused by the disruption of intracellular tight
junctions in the intestine correlates with a high preva-
lence of small intestine bacterial overgrowth [23, 24].
Translocation of normally non-pathogenic bacteria
across the gut may be a driving force of inflammatory
responses associated with IBD [21]. Translocation may
not be purely passive, but may occur via transcellular
pathways activated in enterocytes by inflammatory or
metabolic stress.
It was suggested that in human patients with a higher
than average prevalence of small intestinal bacterial
overgrowth there is an increased bacterial translocation
[25]. Dysregulation of the intestinal immune response
may increase the risk of exposure, something that may
lead them to develop Crohn’s disease [25]. Serum
lipopolysaccharide-binding protein (LBP) is a marker of
disease activity in CD with a similar accuracy as that of
the highly sensitive-CRP. LBP served as an independent
predictor for 1-year clinical flare-up in these patients [26].
Studies have demonstrated that patients with Crohn’s
disease have a shorter bowel length which may predispose
them to the development of the disease via alterations of
intestinal motility and changes in intestinal flora [25].
In the present study oral administration of hyper-
immune colostrum preparations enriched with anti LPS
effectively alleviated immune mediated colitis in mice and
was associated with a significant induction of CD4 +
CD25+ and CD4 + Foxp3+ regulatory T cells in the
spleens of treated mice. Promotion of Tregs by oral
administration of Imm124-E also improved insulin resist-
ance, liver enzymes, hepatic fat accumulation and serum
lipid profiles in mice and in humans [14, 15].
Tregs are critical for maintaining immune homeostasis
and establishing tolerance to foreign, non-pathogenic
antigens including those found in commensal bacteria
and food [27]. Absence of Tregs or defective Treg func-
tion correlate with disease severity [28]. Tregs have sup-
pressive mechanisms and control the threshold for
peripheral antigen recognition via tonic down-regulation
of dendritic cell (DC) co-stimulation. They are also
implicated in maintaining the tolerogenic function of
DCs [29]. Defects in Treg number or function lower
the activation threshold, allowing proliferation and
differentiation of self-reactive CD4 cells. Failure to
maintain the tolerogenic commitment of DCs exposed
to commensal microbes and allergens results in IBD
[29]. Tregs were suggested to be beneficial in the
context of IBD [27].
The human gut microbiome is important for interac-
tions at both the intestinal level and the colonic epithe-
lial cells level, with dendritic cells, and T and B immune
cells [30]. These interactions affect gut barrier and
defense mechanisms. Microbiotic composition may
determine T effector- and Tregs balance and thus
plays a role in the pathogenesis of IBD [30]. Alter-
ations in the gut’s microbiome, acting via Tregs, were
responsible for increased incidence of IBD [29]. Treg-
based immunotherapy could potentially be custom-
designed ad hoc to specifically suit each patient with
limited side effects based on their individual microbial
signatures [31].
A synergistic effect between anti-LPS antibodies and
adjuvants in the colostrum is suggested by the results of
the present study. This notion is based on the effect of
the colostrums enriched with anti LPS antibodies
compared to that of the control group that received
antibody-free colosturm. Bovine colostrum (BC) treat-
ment has been shown to be associated with an increased
number of Tregs [15, 32, 33]. CD25 expression on
peripheral blood monocytes (PBMCs) was enhanced by
treatment with BC-derived IL-1β, TNF-β and IFN-γ
[34]. Exposure to BC increased the percentage of cells
expressing CD11a, CD11c, and CD43 and decreased the
percentage of cells expressing CD62L, which facilitates
lymphocyte trafficking [33, 35]. BC also contains defen-
sin proteins, osteopontin, exosomes, TLRs, cathelicidin,
eosinophil-derived neurotoxin LL-37 and high levels of
β-glycosphingolipids (BGS) [15, 33, 36]. Some of these
mediators serve as mucosal adjuvants, enhancing the
interaction between subsets of antigen presenting cells
and Tregs in the bowel mucosa [37, 38].
The present data suggests that oral antibodies have an
active effect on the adaptive immune system. These re-
sults further support the possibility of altering the adap-
tive immune system by feeding of antibodies. Oral
administration of anti-CD3 both in mice and humans al-
tered the systemic immune response via presentation of
antibodies at the gut level [6, 39, 40].
In summary, oral administration of Imm124E pro-
moted Tregs and alleviated inflammation of the bowel in
the immune-mediated colitis model. The data supports
an association between gut bacterial translocation and
Tregs, and suggests that the microbiome may serve as a
target for Tregs-based immunotherapy.
Conclusions
Study strengths
Shows for the first time the effect of anti-LPS antibodies
in animal model of colitis. It also emphasizes the syner-
gistic effect between anti-LPS antibodies and the potent
colosturm-derived immune adjuvants.
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Study limitations
Some of the parameters tested did not reach statistical
significance and only trends are shown.
Ethics
All animal experiments were performed according to the
guidelines of the Hebrew University-Hadassah Institu-
tional Committee for the Care and Use of Laboratory
Animals and with the approval of the committee.
Availability of data and materials
The data supporting their findings can be found as
Additional file 1.
Additional file
Additional file 1: Supplemenatry file with data of experiments. (XLS
116 kb)
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